Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Oncotarget | Attenuation of Cancer Proliferation by Suppression of Glypican-1

Oncotarget

March 22, 2023
PRESS RELEASE: On March 21, 2023, a new research paper was published in Oncotarget, entitled, “Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.” continue reading »

Oncotarget | Unlocking the Potential of Molecular-Driven Stratification of Osteosarcoma

News

March 20, 2023
PRESS RELEASE: On February 11, 2023, researchers from Université Paris-Saclay published a new editorial paper in Oncotarget, entitled, “Unlocking the potential of molecular-driven stratification for osteosarcoma treatment and prognosis.” continue reading »

Unconventional Protein Secretion (UPS) in Cancer

Oncotarget

March 16, 2023
Researchers from The Jikei University School of Medicine published a recent editorial perspective in Oncotarget, entitled, "Leakage? or Secretion? unconventional protein secretion in cancer."  continue reading »

Oncotarget | MTAP Loss in Metastatic Breast Cancer Patients: Genomic Landscape

News

March 14, 2023
PRESS RELEASE: On March 11, 2023, a new research paper was published in Oncotarget, entitled, “Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss.” continue reading »

Oncotarget | Selective Protection of Normal Cells From Chemotherapy, While Killing Drug-Resistant Cancer Cells

News

March 13, 2023
PRESS RELEASE: On March 11, 2023, Dr. Blagosklonny published a new review in Oncotarget, entitled, “Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells.” continue reading »